Actively Recruiting
The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock
Led by Bach Mai Hospital · Updated on 2025-07-14
108
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
Sponsors
B
Bach Mai Hospital
Lead Sponsor
H
Hanoi Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial examines whether the use of the Swan-Ganz catheter, a specialized pulmonary artery catheter, can improve hemodynamic management and treatment outcomes in patients experiencing cardiogenic shock due to acute myocardial infarction (AMI). Cardiogenic shock is a critical condition marked by the heart's inability to supply adequate blood to the organs, often resulting from a severe heart attack. Despite advancements in care, the condition remains associated with high mortality. Effective monitoring of cardiovascular status is crucial in guiding timely and tailored treatment decisions. Participants in this study will undergo advanced hemodynamic monitoring using the Swan-Ganz catheter, which provides continuous data on cardiac output and other key parameters. This information enables physicians to better assess circulatory function and adjust therapies accordingly. The research will evaluate clinical characteristics, response to treatment, and 30-day outcomes in patients managed with this technique. The study also aims to identify factors associated with successful hemodynamic stabilization and potential complications related to catheter use. A total of 108 adult patients meeting specific eligibility criteria will be enrolled at Bach Mai Hospital over 3 years. Participation is voluntary, and all patients will continue to receive standard-of-care treatment. All personal and medical data will be handled with strict confidentiality.
CONDITIONS
Official Title
The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Provided written informed consent to participate in the study
- Diagnosed with cardiogenic shock due to acute myocardial infarction with systolic blood pressure less than 90 mmHg for at least 30 minutes, or requiring vasopressors to maintain blood pressure above 90 mmHg
- Evidence of end-organ hypoperfusion including altered mental status, urine output less than 30 mL/hour, cold extremities with mottled skin, or serum lactate level above 2 mmol/L
You will not qualify if you...
- Presence of cervical cellulitis
- Inability to identify neck anatomy or history of cervical radiotherapy
- Coagulopathy with INR greater than 1.5 and/or platelet count less than 50 G/L
- End-stage chronic diseases including advanced cancer, advanced-stage HIV, bedridden for more than 3 months, or decompensated liver cirrhosis (Child-Pugh class C)
- Cardiac arrest or mechanical heart complications before catheter insertion
- Congenital heart defects or intracardiac shunts
- Refusal to participate by the patient or their legal representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
BachMai Hospital, Hanoi Medical University
Hanoi, Vietnam, 100000
Actively Recruiting
Research Team
T
Thang Xuan Pham, MD, PhD Candidate
CONTACT
T
Tuan Anh Nguyen, Prof.PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here